INTRODUCTION
The first discovery of cellular mechanisms countering the mutagenic effect of DNA damage actually preceded the discovery of DNA as the genetic material. In an elegantly told story (Friedberg, 1997) , Errol Friedberg described how Albert Kelner stumbled upon photo-reactivation repair of UV lesions at the Cold Spring Harbor laboratory. In his 1949 paper published in PNAS (Kelner, 1949) , Albert Kelner stated:
"While it is premature to do more than to speculate on the mechanism involved in light-induced recovery, the following is suggested as a working hypothesis. Much of the killing effect of ultraviolet-light is due to a light-labile alteration of some constituent in the cell. Exposure to visible light restores this altered constituent to its former state."
The "constituent in the cell" would not be experimentally established as DNA until 1952 when Hershey and Chase presented the conclusion that DNA is the genetic material of the bacteriophage (Hershey and Chase, 1952) .
After DNA was identified as the genetic molecule, the field of DNA damage and mutagenesis has seen its infancy in the early 50s with the term "repair" first used by Salvadore Luria in 1952 (Friedberg, 1997) . Over the past 6 decades, the DNA repair and mutagenesis field has evolved from enzymological study of individual DNA repair activities to the complex molecular network of DNA damage response; from the simple UV survival readout of bacterial and phage to cancer etiology and therapeutics. However, it is fair to say that much of what we know about DNA repair benefited in no small ways from early studies in E. coli and yeasts. The spectacular career of Stephen Elledge also followed a similar path of organismal advance with contributions to the field that few, if any, could match.
FROM E. coli TO HUMANS
The DNA damage response consists of multiple lines of defense against genomic DNA damage, slowing cell cycle progression, modulating DNA repair activities, and utilizing lesion bypass mechanisms to cope with impediments to DNA replication. When Stephen Elledge began his graduate research at MIT with Graham Walker, he was drawn to the DNA damage tolerance and SOS response in E. coli. His work discovered the catalytic subunit of lesion bypass polymerase V (Elledge and Walker, 1983b) , which led to the identification of its regulatory subunit UmuD and its damage inducibility as part of the SOS response (Elledge and Walker, 1983a) . His Ph.D thesis titled "Identification and characterization of genes involved in mutagenesis in Escherichia coli" has set the stage for his subsequent work on the DNA damage response.
After earning his Ph.D degree in 1983, Steve joined Ron Davis laboratory at Stanford University as a Helen Hay Whitney fellow, combining his exceptional genetics skills and the increasingly powerful budding yeast system. He had a clear objective to begin his postdoc work with -to clone the yeast RecA homolog, so that the eukaryotic counterpart of the SOS pathway would be unraveled. As he recounted recently (Elledge, 2015) , an in situ screen of a yeast genomic DNA expression library using E. coli RecA antibodies fortuitously identified the small subunit of ribonuclease reductase (RNR2) gene. Even though RNR expression is highly induced upon DNA damage (Elledge and Davis, 1989) , the cis-element mediating the inducibility does not resemble that of the E. coli lexA gene. His work, however, defined a new mode of regulating DNA damage response genes in eukaryotic cells.
In 1989, Steve was recruited to the faculty of Baylor College of Medicine, where he continued to study the regulatory mechanism controlling RNR expression in response to DNA damage. In a yeast genetic screen for mutants unable to induce RNR genes, the protein kinase DUN1 has emerged as a key regulator of the DNA damage response. This was a first piece of evidence showing that a protein kinase reacts to DNA damage, revealing the signal transduction pathway governing the DNA damage response (Zhou and Elledge, 1993) . Subsequent studies by the Elledge lab has identified the key proteins that mediate damage signaling, revealing a kinase cascade comprised of Mec1, Rad53, and Dun1, and many of their regulators and effectors. By this time, the concept of cell cycle checkpoint had been proposed to explain the delay of cell cycle progression upon DNA damage. Nonetheless, how cells enact such control over the complex cell cycle machinery was by no means perspicacious. In a seminal review in Science, "Cell cycle checkpoints: preventing an identity crisis", Steve formulated his visions of the biochemical nature, signaling mechanisms, and effector engagement of the cell cycle checkpoint (Elledge, 1996) . His visions have played a major role in placing the concept of checkpoint in many different biological contexts, greatly enhancing the appreciation of this cellular process. His predictions turned out to be both visionary and accurate. The main framework of the checkpoint has been proven to be the signal transduction cascade he had envisaged, mediated by protein post-translational modifications through phosphorylation and subsequently expanding to many other forms such as ubiquitination and sumoylation.
While his laboratory was busy delineating the DNA damage checkpoint pathways in yeast, Steve began to shift his attention to the DNA damage response in mammalian cells. The yeast model that he built has paved a solid path to the identification of many mammalian DNA checkpoint proteins, such as CHK1 and CHK2 (Sanchez et al., 1996; Sanchez et al., 1997) . As more and more mammalian checkpoint proteins emerged, the key question regarding checkpoint activation remained -How does the checkpoint recognize the presence of DNA damage and activate the signaling cascade? Given that DNA damages vary tremendously in chemical and structural forms, it is unlikely that a few checkpoint sensing factors are able to recognize all forms of DNA lesions. This fundamental question was answered when the DNA damage-induced binding of RPA, the predominant single-stranded DNA (ssDNA) binding protein in human cells, and ATRIP, the regulatory partner of the checkpoint initiating kinase ATR, was identified (Zou and Elledge, 2003) . By exposing ssDNA, both DNA damage repair intermediates and replication fork stress can trigger checkpoint activation. This paradigm of DNA damage sensing through ssDNA, conserved in both yeast and humans, has revealed a remarkable similarity between the checkpoint response in eukaryotes and the SOS response in bacteria. Steve's work on DNA damage responses from E. coli to humans has completed a full circle.
BEYOND THE CHECKPOINT
In addition to his groundbreaking work on the DNA damage response, Steve has made many seminal contributions to other research areas. For many years, Steve has been a pioneer in the cell cycle field. He was one of the first to identify the CDK inhibitor p21. He has also played a critical role in the discovery of cullin family ubiquitin ligases. In recent years, Steve has been a leader in combined genomic and genetic studies using human cells, making major discoveries in the DNA damage response, protein degradation, cancer therapy, and HIV infection. Steve's achievements are always accompanied by his exceptional aptitude in technology development. Even as a graduate student, he was already significantly accomplished in devising molecular genetics-based functional screens. The λACT cDNA library he designed allowed the yeast two-hybrid system to be deployed as a common protein-protein interaction screening and testing tool in every laboratory (Durfee et al., 1993) . As soon as the RNA interference technology emerged, Steve was among the few leaders who constantly revamped the design and efficiency of this powerful platform. He has provided the field with many crucial resources including the atlas of ubiquitinated proteins and ATM/ATR substrates. More recently, his lab invented a viral infection profiling method that detects a person's "virome" with a minute amount of blood sample (Xu et al., 2015) . The many conceptual and practical innovations in technology advancement broadened his research impact far beyond the genomic instability field.
The field of DNA damage response has experienced tremendous growth. Its impact on cancer etiology and cancer therapy is becoming increasingly clear. The ever-growing knowledge from the DNA damage field has enabled us to better understand how cancer cells evolve, and also to target them based on their intrinsic DNA damage response deficiencies. Direct and indirect DNA-targeting therapies, from proton particle radiation therapy to the ever-improving platinum drugs, may be applied with more efficacies based on the DNA damage response of the tumor. Mechanistic delineation of the DNA damage response also guides the creation of drugs already in clinics, such as PARP inhibitors, or in clinical trials, such as the ATR, CHK1 and WEE1 inhibitors. These advances in improving human health attest to the impactful research of the DNA damage response collectively, and the extraordinary accomplishments of Stephen Elledge who, with Evelyn Witkin, is the most deserving recipient of the 2015 Albert Lasker award for Basic Medical Research.
